Resources

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean for patients and families. There was also an opportunity for questions and answers.

AL amyloidosis can feel overwhelming — but understanding it doesn’t have to be. Join us to learn how the disease is diagnosed, what available treatment options and how to spot signs that the disease may be returning or changing.

Clinical Psychologist, Rosalind Kalb, PhD, joined ARC during Mental Health Month for an important talk covering how we navigate the many emotions that come up when diagnosed and living with amyloidosis.

The Amyloidosis Research Consortium's Executive Director of Research, Kristen Hsu, discussed the current clinical trial landscape in AL amyloidosis. She reviewed trials currently recruiting patients, trials expecting to share results this year, and trials that are planned to open in the future.

Dr. Melissa Hershman joined ARC to discuss how amyloidosis may be affecting your gut, and what you can do about it. There was also an opportunity for questions and answers.

A heart specialist and leader of OHSU’s Cardiac Amyloidosis and Hypertrophic Cardiomyopathy programs, Dr. Masri discussed how imaging plays a key role in identifying amyloidosis and monitoring treatment.

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean for patients and families. There was also an opportunity for questions and answers.

This webinar “Coffee Chat” style webinar is your chance to learn about the different programs and projects ARC has been working on in 2025! Hear directly from ARC staff how we are supporting patients and helping shape the future of amyloidosis.